ArticleJournal of molecular histology2026
Functional role of deubiquitinating enzyme USP39 in inhibiting pyroptosis in human acute myeloid leukemia.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Acute myeloid leukemia (AML) exhibits a five-year overall survival rate below 30%, with its substantial genetic heterogeneity/clonal evolution complicating therapeutic strategies. Pyroptosis, inflammatory programmed cell death via Gasdermins holds therapeutic potential for AML. Deubiquitinase USP39 highly expressed in leukemia and linked to poor prognosis regulates pyroptosis in AML cells via an unclear mechanism. This study aims to explore this mechanism. The TCGA, GTEx, and GSE138702 datasets were applied for analysis of USP family genes differentially expressed. The biological behavior changes of MOLM13 and THP-1 cells after USP39 knockdown were evaluated by MTT, cell cycle, and apoptosis assays. The key genes regulated by USP39 in AML were identified by RNA-seq. Changes in pyroptosis-related pathways indicators after USP39 knockdown were analyzed by ROS detection, ELISA and Western Blot. Adverse prognosis in AML patients exhibited significant correlation with elevated USP39 expression. After USP39 knockdown, cell viability decreased while the level of apoptosis of AML cells increased, with a significant increase in the proportion of G0/G1 phase cells. Mechanistically, RNA-seq identified SQSTM1 as a key target regulated by USP39. USP39 knockdown leads to elevated SQSTM1 levels and significant upregulation of key pyroptotic proteins, with secretions of inflammatory factors increased and ROS accumulated significantly. USP39 inhibits pyroptosis in AML cells by regulating the activation of NLRP3 inflammasome and cleavage of Gasdermin D. The high expression of USP39 is correlated with adverse prognosis in patients, which suggested that USP39 may be an important part of the overall understanding of AML pyroptosis pathways.
Indexed as
Identifiers
41680495What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.